Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aphios Corporation is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. The busiest examiner for the portfolio is PACKARD, BENJAMIN J, who is responsible for 1 busiest examiner pending action. The presence of 2 distinct examiners and 2 distinct art units for 2 pending office actions indicates that each active case is being reviewed by a different individual in a different technical group.
For a company in the Biotechnology & Pharmaceuticals sector, this structure shows a distributed technical scope. The busiest examiner, PACKARD, BENJAMIN J, handles 1 of the pending actions, while the total pending office actions for the company is 2. This distribution requires the company to manage different examiner styles and different art unit standards simultaneously. This approach provides diversity in examiner perspective and technical oversight, which can be beneficial for a portfolio with varied technical applications, though it requires more coordination than a centralized prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PACKARD, BENJAMIN J | 1 | 67.0% | +15.3% |
| SIMMONS, CHRIS E | 1 | 34.1% | +19.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17311633 | METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS | SIMMONS, CHRIS E | 4d overdue |
| 18634819 | Methods For and Products From Encapsulation of Drugs in Nanoparticles in a Microgravity Environment | PACKARD, BENJAMIN J | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18634819 | Methods For and Products From Encapsulation of Drugs in Nanoparticles in a Microgravity Environment | PACKARD, BENJAMIN J | 1612 | §103 | Final Rejection | — | Pending | Apr 12, 2024 |
| 17311633 | METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS | SIMMONS, CHRIS E | 1622 | §103 | Final Rejection | 4d overdue | Pending | Jun 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAphios Corporation has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Benjamin J Packard has the most, with 1 of Aphios Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.